Takeda Pharmaceutical (BOVESPA:TAKP34) - Aktienkurs, Nachrichten und Analyse

TAKP34 Aktienübersicht

Takeda Pharmaceutical Company Limited ist in der Forschung, Entwicklung, Herstellung, Vermarktung und Auslizenzierung von pharmazeutischen Produkten in Japan und international tätig.

Über das Unternehmen

TAKP34 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	3/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	3/6
Dividenden	4/6

Belohnungen

41.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 21.78% pro Jahr

Risikoanalyse

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Die Gewinnspannen (3.4%) sind niedriger als im Vorjahr (7.9%)

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Dividende von 4.69% ist durch die Erträge nicht gut gedeckt

Takeda Pharmaceutical Company Limited Wettbewerber

Hypera

BOVESPA:HYPE3

R$16.9b

Ouro Fino Saúde Animal Participações

BOVESPA:OFSA3

R$1.1b

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹4.7t

Jiangsu Hengrui Medicine

SHSE:600276

CN¥309.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Takeda Pharmaceutical
Historische Aktienkurse
Aktueller Aktienkurs	JP¥80.88
52-Wochen-Hoch	JP¥84.50
52-Wochen-Tief	JP¥66.46
Beta	0.50
11 Monat Veränderung	-4.28%
3 Monate Veränderung	11.21%
1 Jahr Veränderung	4.47%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	15.54%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	TAKP34	BR Pharmaceuticals	BR Markt
7D	0%	-0.07%	1.1%
1Y	4.5%	-13.9%	8.5%

Rendite im Vergleich zur Industrie: TAKP34 übertraf die Branche BR Pharmaceuticals , die im vergangenen Jahr eine Rendite von -10.7 erzielte.

Rendite vs. Markt: TAKP34 hinter dem Markt BR zurück, der im vergangenen Jahr eine Rendite von 7.8 erzielte.

Preisvolatilität

Is TAKP34's price volatile compared to industry and market?
TAKP34 volatility
TAKP34 Average Weekly Movement	4.3%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	4.6%
10% most volatile stocks in BR Market	9.1%
10% least volatile stocks in BR Market	2.3%

Stabiler Aktienkurs: TAKP34 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: TAKP34Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1781	49,281	Christophe Weber	www.takeda.com

Takeda Pharmaceutical Company Limited beschäftigt sich mit der Erforschung, Entwicklung, Herstellung, Vermarktung und Auslizenzierung von pharmazeutischen Produkten in Japan und international. Das Unternehmen bietet pharmazeutische Produkte in den Bereichen Gastroenterologie, seltene Krankheiten, plasmabasierte Therapien, Immunologie, Onkologie und Neurowissenschaften an. Das Unternehmen bietet seine Produkte unter den Namen Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, und Alunbrig.

Takeda Pharmaceutical Company Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Takeda Pharmaceutical im Vergleich zum Marktanteil des Unternehmens?
TAKP34 grundlegende Statistiken
Marktanteil	R$252.21b
Gewinn(TTM)	R$5.73b
Umsatz(TTM)	R$168.70b

44.0x

Kurs-Gewinn-Verhältnis

1.5x

Kurs-Umsatz-Verhältnis

Ist TAKP34 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TAKP34 Gewinn- und Verlustrechnung (TTM)
Einnahmen	JP¥4.41t
Kosten der Einnahmen	JP¥1.50t
Bruttogewinn	JP¥2.92t
Sonstige Ausgaben	JP¥2.77t
Umsatz	JP¥149.92b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Oct 31, 2024

Gewinn per Aktie (EPS)	94.60
Bruttomarge	66.07%
Nettogewinnspanne	3.40%
Schulden/Eigenkapital-Verhältnis	70.3%

Wie hat sich TAKP34 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

4.7%

Aktuelle Dividendenrendite

197%

Ausschüttungsquote

TAKP34 Aktienübersicht

Belohnungen

Risikoanalyse

Takeda Pharmaceutical Company Limited Wettbewerber

BOVESPA:HYPE3

R$16.9b

BOVESPA:OFSA3

R$1.1b

NSEI:SUNPHARMA

₹4.7t

SHSE:600276

CN¥309.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Recent updates

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Takeda Pharmaceutical Company Limited's Grundlagenzusammenfassung

Erträge & Einnahmen